Abstract
Losartan and in-vivo active metabolite losartan carboxylic acid (LCA) formation into systemic circulation have been poorly characterized in different races. A bioequivalence study was therefore conducted on healthy male Indian volunteers with 50 mg losartan formulation and unique comparative analysis with other population is presented. Non-compartmental pharmacokinetic analysis elucidated metabolite formation ratio (MR) for losartan: LCA [Cmax = 1.30 and AUC = 0.32] of 50 mg losartan was more varying compared to innovator [Cmax = 0.82 and AUC = 0.22] though bioequivalence requirements were met successfully. This variation was less for losartan 100 mg losartan- hydrochlorothiazide formulation in our previous published bioequivalence study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
